CNBC May 16, 2024
Key Points
– The Food and Drug Administration on Thursday approved Amgen’s treatment for patients with the most deadly form of lung cancer.
– The agency cleared the drug, called Imdelltra, as a second or later-line treatment for adults with advanced small-cell lung cancer.
– In clinical trials, Amgen’s drug has been shown to reduce tumor growth and help people with small-cell lung cancer live longer.
The Food and Drug Administration on Thursday approved Amgen‘s therapy for patients with the most deadly form of lung cancer.
The agency cleared the drug, which will be marketed under the name Imdelltra, as a second or later line of treatment for people with advanced small-cell lung cancer. That means patients...
Today's Sponsors
Today's Sponsor